Article

Pharmacist initiated intervention trial in osteoarthritis (PhIT-OA): A multidisciplinary intervention for knee osteoarthritis.

Scientist, Centre for Health Evaluation and Outcome Sciences, Providence Health Care Research Institute, Vancouver BC. .
Arthritis care & research 12/2012; 64(12). DOI: 10.1002/acr.21763
Source: PubMed

ABSTRACT BACKGROUND: Knee osteoarthritis (OA) is a commonly undiagnosed condition and care is often not provided. Pharmacists are uniquely placed for launching a multidisciplinary intervention for knee OA. METHODS: A cluster, randomized, controlled trial with pharmacies providing either the intervention or usual care (14 and 18 pharmacies, respectively). The intervention included a validated knee OA screening questionnaire, education, pain medication management, physiotherapy guided exercise and communication with the primary care physician. Usual care consisted of an educational pamphlet. OUTCOMES: The primary outcome was the pass rate on the Arthritis Foundation's quality indicators for OA. Secondary outcomes included the WOMAC, the Lower Extremity Function Scale (LEFS), Paper Adaptive Test-5D (PAT-5D) and Health Utilities Index Mark 3 (HUI3). RESULTS: 139 patients were assigned to the control (n=66) and intervention (n=73). There were no differences between groups in baseline measures. The overall quality indicator pass rate, was significantly higher in the intervention compared to the control arm (difference of 45.2%, 95% CI (34.5, 55.9). Significant improvements were observed for the intervention care group as compared to the usual care in the WOMAC global, pain and function scores at 3 and 6 months (all p<0.01), PAT-5D daily activity scores at three and six months (both p<0.05), PAT-5D pain scores at 6 months (p,0.05), HUI3 single-attribute pain score at 3 and 6 months, (all p<0.05) and the LEFS scores at 6 months (p<0.05). CONCLUSIONS: Pharmacists can launch a multidisciplinary intervention to identify knee OA cases, improve the utilization of treatments, and improve function, pain and QoL. © 2012 by the American College of Rheumatology.

0 Followers
 · 
266 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Medication regimens for asthma are particularly vulnerable to adherence problems because of the requirement for long-term use and periods of symptom remission experienced by patients. Pharmacists are suited to impact medication adherence given their training, skills, and frequent contact with patients. The Empowering pharmacists in asthma management through interactive SMS (EmPhAsIS) trial involves an intervention leveraging mobile health (mHealth) technology to support community pharmacy practice with the hypothesis of improved medication adherence in asthma. This study is a pragmatic pharmacy-based, cluster, randomized controlled trial with 12 months of intervention delivery and follow-up. Pharmacies (the clusters) will be randomized at a 1:1 ratio to provide intervention or usual care. The EmPhAsIS intervention consists of patient asthma education, short message service (SMS)-based monthly assessment of adherence, and follow-up of non-adherent individuals by community pharmacists. There are no inclusion or exclusion criteria for pharmacies. Patients are eligible if they: are 14 years of age or older, fill a prescription for inhaled corticosteroid (either monotherapy or in a combination inhaler with long-acting beta-agonists), have been diagnosed with asthma, possess a mobile phone with SMS capabilities, and have no communication difficulties such as inability to communicate in English, or significant impairment in vision, hearing, or speech. The primary outcome is adherence to inhaled corticosteroids ascertained by the medication possession ratio, the ratio of the days of medication supplied to days in a given time interval. This study will also evaluate secondary outcomes including: asthma control, asthma-related quality of life, asthma-related hospital admissions, and use of reliever medications during the follow-up period. A nested economic evaluation using a probabilistic decision-analytic model will be used to perform a cost-effectiveness analysis from the societal perspective of the intervention compared with usual care over a 10-year time horizon. Considering the prevalence of asthma, the extent of the non-adherence problem in this disease, and the availability of effective treatments, there is a tremendous potential to reduce the burden of asthma through improving adherence. This is the first study of an intervention based on mobile communication technology involving community pharmacists in asthma management.Trial registration: ClinicalTrials.gov identifier: NCT 02170883; date of registration: 19 June 2014.
    Trials 12/2014; 15(1):488. DOI:10.1186/1745-6215-15-488 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: With musculoskeletal conditions now identified as the second highest cause of the morbidity-related global burden of disease, models of care for the prevention and management of disability related to musculoskeletal conditions are an imperative. Musculoskeletal models of care aim to describe how to operationalise evidence-based guidelines for musculoskeletal conditions and thus support implementation by clinical teams and their health systems. This review of models of care for musculoskeletal pain conditions, osteoarthritis, rheumatoid arthritis, osteoporosis and musculoskeletal injuries and trauma outlines health system and local implementation strategies to improve consumer outcomes, including supporting access to multidisciplinary teams, improving access for vulnerable populations and levering digital technologies to support access and self-management. However, the challenge remains of how to inform health system decision-makers and policy about the human and fiscal benefits for broad implementation across health services. Recommendations are made for potential solutions, as well as highlighting where further evidence is required.
    Bailli&egrave re s Best Practice and Research in Clinical Rheumatology 08/2014; 28(3). DOI:10.1016/j.berh.2014.07.001 · 3.06 Impact Factor
  • Source
    Cochrane database of systematic reviews (Online) 01/2015; 1:CD004376. DOI:10.1002/14651858.CD004376.pub3 · 5.94 Impact Factor

Full-text (2 Sources)

Download
122 Downloads
Available from
May 31, 2014